Details
|
|
Daniel W. Rosenberg, Ph.D. HealthNet, Inc. Chair in Cancer Biology and Professor of Medicine, Director, Colon Cancer Prevention Program, Investigator, Center for Molecular Medicine UConn Health Dr. Daniel W. Rosenberg received his B.S. in Biochemistry at SUNY Buffalo and his M.S. Environmental Health/Toxicology from the University of Michigan. He then completed his Ph.D. in Environmental Health Sciences and Toxicology in 1982 through a joint arrangement with the University of Michigan and the Rockefeller University in New York City. After his doctorate, he remained at the Rockefeller University as a Post-Doctoral Fellow in the laboratory of Dr. Attallah Kappas in the Rockefeller University Hospital. After completing his fellowship training, he worked for a brief period as a Toxicologist/Study Director at the Chevron Environmental Health Center in San Pablo, CA. He then returned to the Rockefeller University as an Assistant Professor in the Kappas Laboratory. After almost four years as an Assistant Professor at Rockefeller, he was recruited by the University of Connecticut in Storrs to the Department of Pharmaceutical Sciences in 1991. He was promoted to Associate Professor and awarded academic tenure in 1998. After receiving multiple grants from the NIH, he moved his laboratory to the University of Connecticut School of Medicine in 2000, where he is currently the HealthNet, Inc. Endowed Chair in Cancer Biology and Professor of Medicine. He has maintained an active research program that focuses on gastrointestinal diseases. Dr. Rosenberg has also established a dynamic translational research Program in Colon Cancer Prevention and serves as its Scientific Director. His laboratory's long-term goals are to improve the early detection of cancer, develop population-based studies of colon cancer risk, particularly in young individuals, including inflammatory bowel diseases, and to develop effective chemoprevention strategies for the treatment of high-risk individuals. He has a particular interest in the etiology and progression of the serrated cancer pathway in the right colon, focusing on the characterization of early neoplastic lesions (ACF, serrated polyps) and their associated epigenetic and transcriptional changes. His laboratory research extends across a wide range of research topics in colon cancer biology, applying mouse genetic cancer models to further our understanding of carcinogenic mechanisms, eicosanoid lipid biology and the development and application of new chemoprevention approaches. He has an active collaboration with the laboratory of Dr. George Weinstock at the JLGM, where they are studying the role of natural products, such as tree nuts on the microbial formation of anti-cancer agents and the impact of whole foods on the microbiome. Dr. Rosenberg has served as a standing member of several NIH study sections and is currently a member of NCI PREVENT. He is presently funded by the NIH, the American Institute of Cancer Research, the California Walnut Commission, the Peanut Foundation and Cumberland Pharmaceuticals and has published over 160 papers, primarily in the field of colon cancer etiology and prevention. |